Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia

NCT07112196 is registered in ClinicalTrials.gov with CatalYm GmbH as lead sponsor.

NCT NCT07112196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07112196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
Lead sponsor
CatalYm GmbH
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 16, 2026
Completion date
December 31, 2030
Enrollment
518 (estimated)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

cancer-associated cachexia